Loomis, Sayles & Company’s West Pharmaceutical WST Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $546K | Buy |
+1,521
| New | +$465K | ﹤0.01% | 528 |
|
|
2024
Q1 | – | Sell |
-13
| Closed | -$5K | – | 985 |
|
|
2023
Q4 | $5K | Buy |
+13
| New | +$4.6K | ﹤0.01% | 895 |
|
|
2023
Q1 | – | Sell |
-50
| Closed | -$12K | – | 1036 |
|
|
2022
Q4 | $12K | Buy |
50
+8
| +19% | +$1.9K | ﹤0.01% | 788 |
|
|
2022
Q3 | $10K | Buy |
42
+37
| +740% | +$11.3K | ﹤0.01% | 673 |
|
|
2022
Q2 | $2K | Sell |
5
-9
| -64% | -$2.93K | ﹤0.01% | 900 |
|
|
2022
Q1 | $6K | Buy |
+14
| New | +$5.48K | ﹤0.01% | 777 |
|
|
2021
Q4 | – | Sell |
-35
| Closed | -$15K | – | 916 |
|
|
2021
Q3 | $15K | Buy |
+35
| New | +$14.8K | ﹤0.01% | 749 |
|
|
2021
Q2 | – | Sell |
-50
| Closed | -$14K | – | 926 |
|
|
2021
Q1 | $14K | Buy |
50
+10
| +25% | +$2.86K | ﹤0.01% | 711 |
|
|
2020
Q4 | $11K | Sell |
40
-75,000
| -100% | -$21M | ﹤0.01% | 722 |
|
|
2020
Q3 | $20.6M | Sell |
75,040
-64,777
| -46% | -$17.1M | 0.03% | 228 |
|
|
2020
Q2 | $31.8M | Buy |
139,817
+10,834
| +8% | +$2.13M | 0.05% | 150 |
|
|
2020
Q1 | $19.6M | Sell |
128,983
-1,423
| -1% | -$219K | 0.04% | 167 |
|
|
2019
Q4 | $19.6M | Sell |
130,406
-10,033
| -7% | -$1.46M | 0.03% | 221 |
|
|
2019
Q3 | $19.9M | Buy |
140,439
+12,714
| +10% | +$1.75M | 0.04% | 212 |
|
|
2019
Q2 | $16M | Buy |
127,725
+9,656
| +8% | +$1.14M | 0.03% | 246 |
|
|
2019
Q1 | $13M | Buy |
118,069
+21,539
| +22% | +$2.24M | 0.03% | 299 |
|
|
2018
Q4 | $9.46M | Buy |
96,530
+34,390
| +55% | +$3.73M | 0.02% | 330 |
|
|
2018
Q3 | $7.67M | Buy |
62,140
+794
| +1% | +$89K | 0.02% | 426 |
|
|
2018
Q2 | $6.09M | Sell |
61,346
-2,165
| -3% | -$199K | 0.01% | 509 |
|
|
2018
Q1 | $5.61M | Sell |
63,511
-1,134
| -2% | -$106K | 0.01% | 521 |
|
|
2017
Q4 | $6.38M | Buy |
64,645
+5,253
| +9% | +$515K | 0.01% | 493 |
|
|
2017
Q3 | $5.72M | Sell |
59,392
-1,540
| -3% | -$139K | 0.01% | 506 |
|
|
2017
Q2 | $5.76M | Buy |
60,932
+6,714
| +12% | +$618K | 0.01% | 501 |
|
|
2017
Q1 | $4.42M | Sell |
54,218
-12,878
| -19% | -$1.08M | 0.01% | 525 |
|
|
2016
Q4 | $5.69M | Sell |
67,096
-1,064
| -2% | -$83.7K | 0.01% | 512 |
|
|
2016
Q3 | $5.08M | Sell |
68,160
-17,226
| -20% | -$1.37M | 0.01% | 517 |
|
|
2016
Q2 | $6.48M | Buy |
85,386
+48,916
| +134% | +$3.56M | 0.02% | 480 |
|
|
2016
Q1 | $2.53M | Sell |
36,470
-5,321
| -13% | -$320K | 0.01% | 522 |
|
|
2015
Q4 | $2.52M | Buy |
41,791
+23,972
| +135% | +$1.44M | 0.01% | 531 |
|
|
2015
Q3 | $964K | Buy |
17,819
+5,043
| +39% | +$294K | ﹤0.01% | 556 |
|
|
2015
Q2 | $742K | Buy |
+12,776
| New | +$713K | ﹤0.01% | 590 |
|
Other funds holding WST
GIM
Loomis, Sayles & Company's WST Position: Q2 2026 in Review
Loomis, Sayles & Company opened a new position in West Pharmaceutical (WST) in Q2 2026: 1,521 shares worth $546K. The stake represents ﹤0.01% of the portfolio and ranks #528 among its holdings. This is a return to the name: Loomis, Sayles & Company previously reported a position in WST as recently as Q4 2023.
Loomis, Sayles & Company first reported a position in WST in Q2 2015 and has held it in 31 quarters since. The position peaked at $31.8M in Q2 2020. 831 funds tracked by Wall St. Rank hold WST as of Q2 2026.
- Loomis, Sayles & Company held 1,521 shares of West Pharmaceutical worth $546K as of Q2 2026.
- West Pharmaceutical was a new Loomis, Sayles & Company position in Q2 2026.
- West Pharmaceutical made up ﹤0.01% of Loomis, Sayles & Company's portfolio in Q2 2026, its #528 holding.
- Loomis, Sayles & Company first reported a position in West Pharmaceutical in Q2 2015 and has held it in 31 quarters since.
- Loomis, Sayles & Company's West Pharmaceutical position peaked at $31.8M in Q2 2020.
- 831 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.
Based on Loomis, Sayles & Company's 13F filing for Q2 2026, filed 14 Aug 2026.